BioNTech Results Presentation Deck
Update of Previously Stated Financial Outlook for the 2021 Financial Year
Update on Current Signed COVID-19 Vaccine Order Book for the 2021 Financial Year
Estimated COVID-19 vaccine revenues to BioNTech for the 2021 financial year upon delivery of currently signed
supply contracts (~2.2 billion doses as of July 21, 2021): ~€15.9 billion*
Planned 2021 Financial Year Expenses and Capex*
R&D expenses:
SG&A expenses:
Capital expenditures:
€950 million - €1,050 million
€250 million - €300 million
€175 million - €225 million
37
Ranges reflect current base case projections
Ramp-up of R&D investment in 2H 2021 planned to expand and accelerate the pipeline development
Estimated 2021 Financial Year Tax Assumptions
BioN Tech Group estimated
annual effective income tax rate:
-31%
*Figures have been estimated at constant foreign exchange rates and reflect current base case projections.
BIONTECHView entire presentation